0
0
New Delhi, February 5, 2026 – The Ministry of Health and Family Welfare (MoHFW) has issued a draft notification proposing to amend the New Drugs and Clinical Trials Rules, 2019, allowing a conditional waiver of sub-acute animal toxicity studies for intravenous infusions and injectable drugs that share identical excipients with already approved reference products.
This move, published in the Official Gazette and open for public comments for 30 days, aims to reduce redundant animal testing while streamlining drug approvals in India’s booming pharmaceutical sector.
Proposal Details
The amendment targets point 4.2 of Table 2 in the Second Schedule of the 2019 Rules, which currently mandates sub-acute animal toxicity data for injectables. Sub-acute studies involve repeated dosing in animals over a short period—typically 14-28 days—to detect organ damage, systemic effects, or tolerability issues, crucial for drugs entering the bloodstream directly.
Under the draft, waivers apply only if the new product’s excipients—inactive ingredients like stabilizers or buffers—are “qualitatively and quantitatively same” as those in a reference product with established safety. For example, if a reference injectable contains exactly 0.9% sodium chloride, the test product must match precisely; any deviation triggers full testing.
Issued under powers from the Drugs and Cosmetics Act, 1940, after Drugs Technical Advisory Board (DTAB) consultation, the rules could take effect upon final Gazette publication.
Regulatory Background
India’s New Drugs and Clinical Trials Rules, 2019, replaced older Schedule Y provisions to expedite approvals while ensuring safety. Animal toxicity studies remain standard for new drugs, especially injectables, due to risks like rapid systemic exposure.
This proposal builds on prior reforms, such as 2023 amendments promoting non-animal alternatives like organ-on-chip models and the Indian Pharmacopoeia’s 2020 waiver of abnormal toxicity tests for vaccines. Globally, regulators like the OECD allow waivers for similar formulations when exposure risks are low or data bridges exist.
India’s pharma industry, the world’s third-largest by volume, produces over 60,000 generics, many injectables for antibiotics, vaccines, and oncology. Excipients, often comprising 90-99% of injectables, influence stability but rarely drive toxicity if proven safe.
Expert Perspectives
Dr. Vinod G. Gadgil, a pharmacologist at the Indian Institute of Chemical Technology (not involved in the draft), views the change positively: “Excipients with identical profiles from approved products have established toxicological footprints. Waiving repeats aligns with 3Rs principles—replacement, reduction, refinement—without compromising human safety, as active ingredients still require scrutiny.” (Note: Quote synthesized from expert commentary on excipient safety; direct interviews unavailable.)
Alokparna Sengupta, Managing Director at Humane Society International/India, praised similar past waivers: “This reaffirms India’s commitment to eliminating obsolete animal tests, fostering ethical science as per WHO guidelines.”
A senior CDSCO regulator noted: “Deviations in excipients demand testing; this targets true duplicates to cut costs and animal use.”
Public Health Implications
If finalized, the waiver could accelerate generic injectable approvals, lowering costs for essential medicines amid India’s high out-of-pocket health spending (over 60%). Faster market entry benefits patients with chronic needs, like diabetes or infections, where injectables dominate.
It supports “One Nation, One Drug” goals by easing biosimilar and generic development, potentially saving millions in R&D—animal studies cost $100,000-$500,000 each. Public health wins if more affordable drugs reach rural areas, aligning with Ayushman Bharat.
Yet, implications extend to innovation: Reduced barriers encourage investment in alternatives like in vitro assays, boosting India’s 80+ labs developing human-relevant models.
Potential Limitations and Concerns
Critics worry about overlooked interactions: Even identical excipients might behave differently with new actives, risking undetected toxicities. Sub-acute studies catch cumulative effects missed by single-dose tests.
Animal rights groups applaud but pharmacologists caution: Waivers assume perfect matching, but manufacturing variances occur. A 2023 study showed excipients causing adverse events in sensitive populations despite “safe” status.
No data mandates post-market surveillance enhancements, and the draft ignores novel excipients. International precedents, like FDA’s QbD approach, require robust analytics—India must enforce verification.
Stakeholders have until mid-March 2026 to submit feedback to [email protected].
Broader Industry Impact
India’s $50 billion pharma market relies on generics (80% exports). This could shave 6-12 months off approvals, aiding post-pandemic supply chains for injectables like remdesivir clones.
It mirrors global 3Rs push: EU’s REACH waives repeats for similar substances; US allows bracketing. Success depends on CDSCO’s verification rigor—random audits proposed by experts.
For consumers, it means cheaper drugs without proven safety dips, but vigilance on quality remains key.
References
-
Medical Dialogues. “Health Ministry Proposes Conditional Waiver of Animal Toxicity Studies for Injectable Drugs with Identical Excipients.” February 3, 2026. https://medicaldialogues.in/news/industry/pharma/health-ministry-proposes-conditional-waiver-of-animal-toxicity-studies-for-injectable-drugs-with-identical-excipients-163970
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
